Last reviewed 2026-04-23 · How we verify

Intravenous Levonadifloxacin/Linezolid Infusion

Intravenous Levonadifloxacin/Linezolid Infusion is a Fluoroquinolone/Oxazolidinone combination antibiotic Small molecule drug developed by Wockhardt. It is currently in Phase 3 development for Complicated skin and soft tissue infections, Hospital-acquired pneumonia, Community-acquired pneumonia with resistant pathogens.

This combination drug pairs a fluoroquinolone antibiotic (levonadifloxacin) that inhibits bacterial DNA gyrase with linezolid, an oxazolidinone that inhibits bacterial protein synthesis, to provide broad-spectrum coverage against gram-positive and gram-negative bacteria.

This combination drug pairs a fluoroquinolone antibiotic (levonadifloxacin) that inhibits bacterial DNA gyrase with linezolid, an oxazolidinone that inhibits bacterial protein synthesis, to provide broad-spectrum coverage against gram-positive and gram-negative bacteria. Used for Complicated skin and soft tissue infections, Hospital-acquired pneumonia, Community-acquired pneumonia with resistant pathogens.

At a glance

Mechanism of action

Levonadifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The combination provides synergistic activity against resistant pathogens, particularly gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

Approved indications

• Complicated skin and soft tissue infections
• Hospital-acquired pneumonia
• Community-acquired pneumonia with resistant pathogens

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Headache
• Peripheral neuropathy (linezolid-related)
• Thrombocytopenia (linezolid-related)
• QT prolongation (fluoroquinolone-related)

Key clinical trials

• Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Intravenous Levonadifloxacin/Linezolid Infusion CI brief — competitive landscape report
• Intravenous Levonadifloxacin/Linezolid Infusion updates RSS · CI watch RSS
• Wockhardt portfolio CI

Frequently asked questions about Intravenous Levonadifloxacin/Linezolid Infusion

Related

• Drug class: All Fluoroquinolone/Oxazolidinone combination antibiotic drugs
• Target: All drugs targeting Bacterial DNA gyrase, topoisomerase IV, 50S ribosomal subunit
• Manufacturer: Wockhardt — full pipeline
• Therapeutic area: All drugs in Infectious Disease
• Indication: Drugs for Complicated skin and soft tissue infections
• Indication: Drugs for Hospital-acquired pneumonia
• Indication: Drugs for Community-acquired pneumonia with resistant pathogens
• Compare: Intravenous Levonadifloxacin/Linezolid Infusion vs similar drugs
• Pricing: Intravenous Levonadifloxacin/Linezolid Infusion cost, discount & access